AstraZeneca said its COVID-19 vaccine was 76% effective at preventing symptomatic illness in a new analysis of its major U.S.
trial — a tad lower than the level announced earlier this week in a report that was criticized for using outdated information.U.S.
health officials had publicly rebuked the drugmaker for not using the most up-to-date information when it published an interim analysis on Monday that said the vaccine was 79% effective.
Can AstraZeneca’s reputation be saved? Experts worry ‘unforced errors’ erode trust The latest data was based on 190 infections among more than 32,400 participants in the United States, Chile and Peru.